PPARA and hypertriglyceridemia: Thus, this model was chosen in this study to examine the preventive activity of EPE in diabetic mice compared with that of other clinical drugs, namely, an oral hypoglycemic sulfonylurea, glibenclamide (Glib) (Glib is not recommended for the treatment of T1DM since it can directly stimulate insulin release from β cells) (30), and a hypotriglyceridemic drug, fenofibrate (Feno), which was the drug chosen for the treatment of hypertriglyceridemia and is a peroxisome proliferator-activated receptor (PPAR) α agonist (31, 32).